Compare TRDA & ELVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | ELVA |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.3M | 328.2M |
| IPO Year | 2021 | 2021 |
| Metric | TRDA | ELVA |
|---|---|---|
| Price | $4.65 | $3.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $17.75 | $13.60 |
| AVG Volume (30 Days) | ★ 449.9K | 395.2K |
| Earning Date | 11-05-2026 | 12-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,421,000.00 | N/A |
| Revenue This Year | N/A | $10.18 |
| Revenue Next Year | $361.69 | $32.63 |
| P/E Ratio | ★ N/A | $78.51 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.11 | $3.68 |
| 52 Week High | $16.45 | $12.78 |
| Indicator | TRDA | ELVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 28.60 |
| Support Level | $4.18 | N/A |
| Resistance Level | $5.13 | $6.85 |
| Average True Range (ATR) | 0.51 | 0.39 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 23.15 | 1.82 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.